The Eli Lilly Lawsuit: What Nobody’s Saying About Compound GLP-1 Safety
Editor’s Note: I originally recorded these thoughts back in April 2025 when Eli Lilly filed their latest round of lawsuits against compound pharmacies. Nine months later, this legal battle is still unfolding—and everything I said then matters even more now. Rather than rewrite what I captured in the moment, I’m sharing the video below and expanding on it here, because the core safety concerns I raised haven’t changed. What has changed is that we now have even more clarity about what’s at stake for the women navigating this impossible situation.
I know this is going to be controversial. I know most people on social media aren’t saying what I’m about to say. But I need you to hear me out before you react.
First, full disclosure: I’m not affiliated with any GLP-1 provider. Not compound, not brand name, nothing. I paid $9,900 out of pocket for Zepbound until I got it covered by insurance for Sleep Apnea in May 2025. I understand the weight of these decisions because I’m had to make them as well.
What’s Actually Happening With These Lawsuits
Eli Lilly just served another round of lawsuits, and this one is different. This isn’t about patent infringement like the previous cases. This time, they’re specifically targeting the safety of compounded medications.
Their argument? Compound providers are mixing tirzepatide with other additives that haven’t been tested for safety. And technically, that’s the only way compounded medications are supposed to be distributed—when there’s a legitimate need for a specific variation.
The Problem I’ve Been Watching Unfold
Once the FDA cleared the shortage and compounded tirzepatide was no longer legally available, something shifted. I started seeing what looked like a massive clearance sale.
My DMs filled with people trying to sell medication. My email inbox exploded with promotional offers—sometimes multiple times per day. My entire social media feed turned into aggressive marketing for bulk purchases of compound meds.
Here’s what bothered me most: these ads weren’t targeting existing patients. They were targeting people who’d never been on GLP-1s before. The message was clear—get it while you can.
But there was never a conversation about what happens after. No discussion of this being a lifestyle medication. No plan for when the supply runs out. Just “buy three months in bulk” and figure it out later.
What Compounding Was Actually Designed For
True medical compounding exists for specific, legitimate reasons. A patient needs a liquid form instead of a pill. Someone requires a specific formulation not available at regular pharmacies. These are individualized medical needs.
The telehealth GLP-1 model stretched that definition to its breaking point. I understand why—these companies invested heavily in this business model. But how long did they really think this would last? And more importantly, what was their plan for patient care when it inevitably ended?
The Safety Issues Nobody Wants to Talk About
I actually went through the process of getting compound medication once during the Spring of 2024 shortage. The ease of access shocked me.
Fill out a form. Send a photo. Consent that you’re not taking conflicting medications—based on your own knowledge, with no verification. Sometimes you could speak with a provider. Most times you didn’t have to. No comprehensive health history review.
Now, as both Zepbound and Wegovy are off the shortage list, companies are advertising that you could get three months of the same dose with zero conversation about titration, side effect management, or what happens when you run out and suddenly have no more access to your medication because the cost of brand name is unreasonable.
There is no transition plan. No prescription counseling of what to expect. I’m not even sure if newly onboarding patients understand that everyone in the compound world is literally just waiting on bated breath for when this all gets shut down.
Where I Stand (And Why This Is Complicated)
I recognize that for many people, compound medications were the only affordable option. That access mattered. It changed lives.
I also recognize that plenty of people get brand name prescriptions from doctors who provide just as little support and guidance.
But the aggressive marketing, the bulk selling without safety protocols, the onboarding of new patients with no long-term plan—that infrastructure wasn’t built for patient care. It was built for business.
And when Eli Lilly argues that these compound mixes haven’t been tested for safety, that combining certain additives with tirzepatide carries unknown risks, that patients are receiving these medications without proper medical oversight—there’s validity to that concern.
Even if we don’t like the messenger.
What This Means for You
If you’ve been relying on compound medication and it’s no longer available, I know this is incredibly difficult. You made the best choice you could with the options available to you.
Now you’re facing hard decisions again.
Consider exploring:
- Oral Wegovy:
- Starting Dose: 1.5 mg – $149/month
- Until 4/15/26: 4.0 mg – $149/month
- After 4/15/26: 4.0 mg – $199/month
- 9mg & 25mg – $299/month
- Wegovy Pen:
- 0.25mg, 0.5mg – $199/ month for first 2 fills (intro pricing), $349/month after
- All other doses – $499/month
- Zepbound single-dose vials (from Lily Direct):
- 2.5 mg – $299/month
- 5.0 mg – $399/month
- 7.5 mg – $449/month
- 10 mg – $449/month
- 12.5 mg- $449/month
- 15 mg – $449/month
- Zepbound Auto-Injector:
- All doses – $499/month (with savings card)
I know this is a terrible situation all around, but its important to start finding the next best option for you with your medical provider and make sure there is a plan in place.
The Uncomfortable Truth
Eli Lilly has made plenty of questionable decisions. Their pricing strategy is absurd. Their approach to patient access is frustrating.
You deserved better infrastructure. You deserved a plan. You deserved to be treated like more than a revenue stream during a limited window of opportunity.
And you still deserve support now.
I’m here for the long game. For the women who need strategy, clarity, and a system that actually holds. Whether you’re on brand name, compound, switching between them, or figuring out your next move.
This journey is complex. Your decision-making deserves to be honored as complex too.
xo, Coach Insiya
Your GLP-1 Strategist & Mindset Coach
